FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895590704> ?p ?o ?g. }

• W2895590704 endingPage "810" @default.
• W2895590704 startingPage "803" @default.
• W2895590704 abstract "In patients with ulcerative colitis (UC), fecal calprotectin (FC) concentrations correlate with endoscopic inflammation evidence. This study investigated the effect of vedolizumab induction on FC concentrations and whether FC concentrations could be a reliable surrogate measure of disease status.Data from the placebo-controlled, phase 3 trial GEMINI 1 were used to evaluate week-6 relationships between outcomes (including clinical remission, mucosal healing [MH], and endoscopic remission) and both absolute FC concentration values and relative FC concentration changes from baseline (%FC0-6). Sensitivity and specificity were calculated by cross-tabulation; the value of week-6 FC concentration as surrogate biomarker was measured with Youden J statistic computed for various cut points.GEMINI 1 induction phase enrolled 895 patients. Fecal calprotectin concentration decreases were deeper in patients with clinical remission, MH, and/or endoscopic remission than in patients without. The best week-6 indicator of clinical or endoscopic remission in this data set was absolute FC concentration ≤150 µg/g. The surrogate biomarker values (based on areas under the curve) for the best-performing cut points (FC0-6 reduction >90%, FC ≤150 µg/g) were fair (range, 0.70-0.77, total population). More patients met the ≤150 µg/g cut point with vedolizumab than with placebo. Baseline FC concentrations were not correlated with clinical outcomes.Fecal calprotectin concentration reductions were greater with vedolizumab induction than with placebo. Week-6 FC concentrations had only fair surrogate biomarker value for endoscopic status. Our data suggest that, while FC may reflect inflammatory burden, FC concentration after vedolizumab induction may not be a robust biomarker of mucosal inflammation." @default.
• W2895590704 created "2018-10-12" @default.
• W2895590704 creator A5004810604 @default.
• W2895590704 creator A5013058329 @default.
• W2895590704 creator A5017140014 @default.
• W2895590704 creator A5019678358 @default.
• W2895590704 creator A5036411840 @default.
• W2895590704 creator A5038005848 @default.
• W2895590704 creator A5038652207 @default.
• W2895590704 creator A5041912518 @default.
• W2895590704 creator A5041936168 @default.
• W2895590704 creator A5047563454 @default.
• W2895590704 creator A5048464948 @default.
• W2895590704 creator A5057082655 @default.
• W2895590704 creator A5058615224 @default.
• W2895590704 creator A5062818239 @default.
• W2895590704 creator A5090664195 @default.
• W2895590704 date "2018-10-05" @default.
• W2895590704 modified "2023-10-14" @default.
• W2895590704 title "Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1" @default.
• W2895590704 cites W1738875030 @default.
• W2895590704 cites W1921717516 @default.
• W2895590704 cites W1974861015 @default.
• W2895590704 cites W2024121629 @default.
• W2895590704 cites W2024247458 @default.
• W2895590704 cites W2036503241 @default.
• W2895590704 cites W2043078815 @default.
• W2895590704 cites W2057618437 @default.
• W2895590704 cites W2059127937 @default.
• W2895590704 cites W2067671146 @default.
• W2895590704 cites W2072766425 @default.
• W2895590704 cites W2091592849 @default.
• W2895590704 cites W2105857910 @default.
• W2895590704 cites W2121569640 @default.
• W2895590704 cites W2132505655 @default.
• W2895590704 cites W2149170290 @default.
• W2895590704 cites W2152575748 @default.
• W2895590704 cites W2159561736 @default.
• W2895590704 cites W2160240762 @default.
• W2895590704 cites W2160619682 @default.
• W2895590704 cites W2161661686 @default.
• W2895590704 cites W2162805528 @default.
• W2895590704 cites W2165294540 @default.
• W2895590704 cites W2329755771 @default.
• W2895590704 cites W2330470789 @default.
• W2895590704 cites W2340591593 @default.
• W2895590704 cites W2406401379 @default.
• W2895590704 cites W2519618731 @default.
• W2895590704 cites W2615644319 @default.
• W2895590704 cites W2756793032 @default.
• W2895590704 cites W2767757130 @default.
• W2895590704 cites W2787397416 @default.
• W2895590704 cites W3015877068 @default.
• W2895590704 cites W4211138554 @default.
• W2895590704 cites W4230633180 @default.
• W2895590704 doi "https://doi.org/10.1093/ibd/izy304" @default.
• W2895590704 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6416826" @default.
• W2895590704 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30295811" @default.
• W2895590704 hasPublicationYear "2018" @default.
• W2895590704 type Work @default.
• W2895590704 sameAs 2895590704 @default.
• W2895590704 citedByCount "26" @default.
• W2895590704 countsByYear W28955907042019 @default.
• W2895590704 countsByYear W28955907042020 @default.
• W2895590704 countsByYear W28955907042021 @default.
• W2895590704 countsByYear W28955907042022 @default.
• W2895590704 countsByYear W28955907042023 @default.
• W2895590704 crossrefType "journal-article" @default.
• W2895590704 hasAuthorship W2895590704A5004810604 @default.
• W2895590704 hasAuthorship W2895590704A5013058329 @default.
• W2895590704 hasAuthorship W2895590704A5017140014 @default.
• W2895590704 hasAuthorship W2895590704A5019678358 @default.
• W2895590704 hasAuthorship W2895590704A5036411840 @default.
• W2895590704 hasAuthorship W2895590704A5038005848 @default.
• W2895590704 hasAuthorship W2895590704A5038652207 @default.
• W2895590704 hasAuthorship W2895590704A5041912518 @default.
• W2895590704 hasAuthorship W2895590704A5041936168 @default.
• W2895590704 hasAuthorship W2895590704A5047563454 @default.
• W2895590704 hasAuthorship W2895590704A5048464948 @default.
• W2895590704 hasAuthorship W2895590704A5057082655 @default.
• W2895590704 hasAuthorship W2895590704A5058615224 @default.
• W2895590704 hasAuthorship W2895590704A5062818239 @default.
• W2895590704 hasAuthorship W2895590704A5090664195 @default.
• W2895590704 hasBestOaLocation W28955907041 @default.
• W2895590704 hasConcept C126322002 @default.
• W2895590704 hasConcept C141341695 @default.
• W2895590704 hasConcept C142724271 @default.
• W2895590704 hasConcept C185592680 @default.
• W2895590704 hasConcept C204787440 @default.
• W2895590704 hasConcept C27081682 @default.
• W2895590704 hasConcept C2776207728 @default.
• W2895590704 hasConcept C2778260677 @default.
• W2895590704 hasConcept C2778292693 @default.
• W2895590704 hasConcept C2779008522 @default.
• W2895590704 hasConcept C2779134260 @default.
• W2895590704 hasConcept C2780479503 @default.
• W2895590704 hasConcept C2781197716 @default.
• W2895590704 hasConcept C2908647359 @default.

• next